Financial Performance - The company's operating revenue for 2024 was CNY 1,108,948,700.11, representing a 6.27% increase compared to CNY 1,043,506,694.32 in 2023[16] - The net profit attributable to shareholders for 2024 was CNY 254,863,444.95, a decrease of 2.53% from CNY 261,484,433.37 in 2023[16] - The net profit after deducting non-recurring gains and losses was CNY 233,087,950.27, down 2.45% from CNY 238,952,550.49 in the previous year[16] - The net cash flow from operating activities increased by 14.44% to CNY 341,845,598.08, compared to CNY 298,715,870.41 in 2023[16] - The total assets at the end of 2024 were CNY 2,064,801,711.06, reflecting a 6.71% increase from CNY 1,934,881,553.02 at the end of 2023[16] - The net assets attributable to shareholders increased by 8.22% to CNY 1,843,264,757.86, compared to CNY 1,703,320,906.08 in 2023[16] - The basic earnings per share for 2024 were CNY 0.64, a decrease of 3.03% from CNY 0.66 in 2023[16] - The company reported a total non-operating income of approximately $21.78 million, a decrease from $22.53 million in 2023, and significantly lower than $106.76 million in 2022[22] - The company achieved a revenue of 776.71 million CNY in the domestic market for 2024, earning the title of "National Manufacturing Single Champion" [62] - The revenue from drug clinical research services surged by 81.38% year-on-year, amounting to ¥160,896,610.26, up from ¥88,706,635.50 in 2023[66] - Domestic sales slightly decreased by 1.08% to ¥776,706,105.56, while international sales increased by 28.61% to ¥332,242,594.55[69] - The gross profit margin for the in vitro diagnostic industry was 84.75%, reflecting a year-on-year increase of 0.78%[70] R&D and Innovation - R&D investment reached 216.11 million yuan, accounting for 19.49% of revenue, with a year-on-year growth of 6.35%[53] - The company holds 32 Class III medical device registrations and 68 patents, including 62 invention patents, demonstrating its strong innovation capabilities[53] - The company has developed a comprehensive R&D team of 523 members, focusing on various disciplines to drive efficient project management and innovation[53] - The company is actively involved in research and development, aiming to innovate new products and technologies[126] - The company has completed the development of multiple gene testing kits, enhancing its product line and core competitiveness[81] - The company has launched a new high-throughput gene sequencing instrument, ADx-SEQ200 Plus, which offers a cost-effective solution compared to imported brands[38] - The company has introduced a real-time fluorescence quantitative PCR analyzer, GEMINI, which doubles throughput and simplifies operations for tumor precision diagnostics[38] - The company has developed and received approval for 32 tumor gene detection products, making it a leading enterprise in the industry with the most comprehensive product range[32] Market and Strategic Focus - The company’s strategic focus on precision medicine aligns with the growing demand for tumor gene testing, which has expanded from drug guidance to comprehensive patient lifecycle management[25] - The global cancer incidence is approximately 20 million new cases annually, with China accounting for over 4.8 million new cases, representing about 24% of the global total[26] - The proportion of targeted and immunotherapy drugs in the global oncology drug development pipeline has exceeded 50%, driving rapid growth in related gene testing demand[27] - The company has formed strategic partnerships with over 100 international distributors, enhancing its global operational network [63] - The company has established a direct sales network covering over 500 top hospitals in China, supported by a professional team of nearly 400 people [57] - The company has successfully registered three Class III (CDx) products in overseas markets, including the ROS1 Gene Fusions Detection Kit and the AmoyDx® Pan Lung Cancer Gene PCR panel, which are covered by health insurance in Japan and South Korea[41] Regulatory and Compliance - The regulatory environment is increasingly emphasizing compliance, which is expected to elevate industry standards and concentration, benefiting the company[29] - The company emphasizes strict production and quality control processes, ensuring compliance with regulatory standards and maintaining product quality[48] - The company has established a policy monitoring mechanism to respond to potential regulatory risks[105] - The company has established a comprehensive internal control system, ensuring the legality and compliance of operations, with no significant defects found in financial reporting controls during the reporting period[166] Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal regulations and the company's articles of association[115] - The company has established specialized committees under the board of directors, including the audit committee and the strategic development committee, to enhance governance effectiveness[114] - The company has a performance evaluation and incentive mechanism that aligns with its development status, ensuring transparency in the hiring and assessment of senior management[116] - The company has experienced changes in its board and management personnel, indicating a shift in governance and operational strategy[122] - The company’s independent directors bring significant academic and industry experience, contributing to its governance[128][129][130] Employee and Training Development - The total number of employees at the end of the reporting period is 1,144, including 683 at the parent company and 461 at major subsidiaries[155] - The professional composition includes 523 technical personnel, 371 sales personnel, and 111 production personnel, among others[156] - The educational background of employees shows 25 with a doctorate, 251 with a master's degree, and 868 with a bachelor's degree or below[156] - The company emphasizes employee development through a structured training system and a scientific incentive mechanism, fostering a positive work environment[175] - The company has actively integrated high-quality training resources to enhance employee skills and overall team capabilities, supporting sustainable development[158] Environmental and Social Responsibility - The company adheres to environmental protection laws and has established a comprehensive environmental management system, focusing on low-carbon and sustainable development[172] - The company actively engages in public welfare activities related to cancer prevention and awareness, contributing to early screening and diagnosis efforts[175] - The company integrates environmental considerations throughout the project lifecycle, aligning with national carbon neutrality goals[175] - The company has not reported any administrative penalties related to environmental issues during the reporting period[172] Cash Dividend and Profit Distribution - The company maintained a cash dividend policy with a total cash dividend amount of ¥117,918,590.70, which represents 100% of the total profit distribution[161] - For the 2024 profit distribution plan, the company proposed a cash dividend of ¥3 per 10 shares (including tax), with no stock dividends or capital reserve transfers[163] - The company’s profit distribution policy has remained unchanged during the reporting period, ensuring clarity and completeness in decision-making processes[161] - The company has implemented a reasonable profit distribution and cash dividend policy, ensuring the protection of investor rights and interests[175] Financial Management and Audit - The company has engaged Lixin Accounting Firm for auditing services, with a fee of 1 million yuan and a continuous service period of 10 years[183] - The company has appointed Lixin Accounting Firm as the internal control auditing firm, with an internal control audit fee of 200,000 yuan[184] - The internal control evaluation report indicates that all evaluated units accounted for 100% of the company's total assets and revenue[168] - The company has committed to strengthen internal controls and improve management levels to ensure normal operations and reduce management risks[179]

Financial Performance - The company's revenue for Q1 2025 was ¥272,090,793.91, representing a 16.63% increase compared to ¥233,288,808.06 in the same period last year[5] - Net profit attributable to shareholders was ¥90,471,778.52, a 40.92% increase from ¥64,199,068.03 year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥87,223,537.32, up 53.07% from ¥56,981,941.60 in the previous year[5] - Basic and diluted earnings per share were both ¥0.23, a 43.75% increase from ¥0.16 in the previous year[5] - Total operating revenue for the current period reached ¥272,090,793.91, an increase of 16.6% compared to ¥233,288,808.06 in the previous period[20] - Net profit for the current period was ¥90,471,778.52, representing a significant increase of 40.9% from ¥64,199,068.03 in the previous period[21] - The company's profit before tax was ¥101,793,500.12, an increase of 38.3% from ¥73,566,224.34 in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities was ¥103,254,852.84, reflecting a 28.14% increase compared to ¥80,577,903.10 in the same period last year[5] - Operating cash flow increased to 103,254,852.84 from 80,577,903.10, a rise of 28.06%[22] - Total cash inflow from operating activities reached 290,859,140.41, compared to 273,690,053.97 in the previous period, marking a 6.25% increase[22] - Cash and cash equivalents at the end of the period decreased to 288,933,634.09 from 323,750,184.55, a drop of 10.76%[23] - The company reported a net increase in cash and cash equivalents of -26,528,201.73, contrasting with a net increase of 122,672,317.88 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,163,512,829.30, a 4.78% increase from ¥2,064,801,711.06 at the end of the previous year[5] - Total liabilities rose to ¥244,665,855.76, compared to ¥221,536,953.20, indicating an increase of 10.4%[18] - The company's total assets increased to ¥2,163,512,829.30 from ¥2,064,801,711.06, marking a growth of 4.8%[18] - Total current assets increased to ¥1,891,421,886.64 from ¥1,788,399,896.77[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 24,012[12] - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 22.31% of shares, totaling 87,701,616 shares[12] - The total number of shares held by the top ten unrestricted shareholders is 87,701,616, with Forward Investment (Hong Kong) Limited being the largest[13] - The total number of restricted shares at the end of the period is 3,464,606, down from 3,527,230 due to the unlocking of shares[14] - The company has no reported related party relationships or concerted actions among the top shareholders[13] Expenses and Investments - Total operating costs amounted to ¥171,878,070.83, up from ¥167,788,210.58, reflecting a growth of 1.3%[20] - Research and development expenses were ¥41,536,126.88, a decrease of 14.1% from ¥48,363,080.43 in the previous period[20] - The company has a long-term investment of ¥10,497,291.81, down from ¥11,951,810.18[16] - The financial expenses showed a significant improvement, with a net income of -¥10,374,808.85 compared to -¥3,263,353.11 previously[20] Future Plans and Accounting Changes - The company plans to continue its market expansion and product development strategies, although specific details were not disclosed in the provided content[15] - The company plans to adopt new accounting standards starting in 2025, which may impact future financial reporting[24] - The first quarter report was not audited, indicating a preliminary assessment of financial performance[24]

证券代码：300685 证券简称：艾德生物 公告编号：2025-019 厦门艾德生物医药科技股份有限公司 关于 2024 年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 以未来实施 2024 年度权益分配方案时股权登记日的总股本（扣除回购专用证券账 户股份）为基数，向全体股东每 10 股派发现金红利 3 元（含税），预计共派发现金红利 117,918,590.701元（含税），不送红股，不以资本公积金转增股本。 一、审议程序 厦门艾德生物医药科技股份有限公司（以下简称"艾德生物"或"公司"） 于 2025 年 4 月 19 日召开第四届董事会第六次会议及第四届监事会第五次会议， 审议通过了《关于 2024 年度利润分配方案的议案》。本议案尚需提交公司 2024 年度股东大会审议。 二、利润分配方案的基本情况 1、本次利润分配为公司 2024 年度利润分配。 2、根据《公司法》和《公司章程》的有关规定，2024 年提取法定盈余公积 金 21,265,143.33 元。经立信会计师事务所（特殊普通合伙）审计，截至 2024 年 ...

Group 1 - The core viewpoint of the article highlights the financial performance of Aide Biological (300685) in the first quarter of 2025, showing significant growth in both revenue and net profit [1] Group 2 - The company's revenue for Q1 2025 reached 272 million yuan, representing a year-on-year increase of 16.63% [1] - The net profit for the same period was 90.4718 million yuan, reflecting a year-on-year growth of 40.92% [1]

Company Overview - Xiamen Ade Biological Technology Co., Ltd. specializes in the research, production, and sales of molecular diagnostic products for precision oncology, providing related testing services [2] - The company's main products include molecular diagnostic reagents for targeted cancer therapy and chemotherapy, which help clinicians develop personalized treatment plans based on the genetic status of cancer patients [2] Financial Performance - For the third quarter of 2024, the company reported a revenue of 848 million yuan, representing a year-on-year increase of 19.84% [3] - The net profit for the same period was 227 million yuan, showing a year-on-year growth of 30.82% [3] - The sales gross margin stood at 84.74% [3] Market Position - As of the latest data, the company's rolling price-to-earnings (PE) ratio is 28.56, while the average PE ratio in the medical device industry is 46.48, and the industry median is 31.96 [1][3] - The total market capitalization of the company is approximately 8.997 billion yuan [1] Institutional Holdings - As of the third quarter of 2024, a total of 264 institutions hold shares in the company, including 263 funds and 1 brokerage, with a total holding of 63.719 million shares valued at 1.453 billion yuan [1]

Company Overview - Xiamen Ade Biological Technology Co., Ltd. specializes in the research, production, and sales of molecular diagnostic products for precision oncology, providing related testing services [2] - The company's main products include targeted drug molecular diagnostic reagents and chemotherapy drug molecular diagnostic reagents, which are used to assess the genetic status of cancer patients [2] - The company holds multiple qualifications, including "National High-tech Enterprise" and "National Enterprise Technology Center," and has received various awards for its research and development efforts [2] Financial Performance - For the third quarter of 2024, the company reported revenue of 848 million yuan, representing a year-on-year increase of 19.84% [3] - The net profit for the same period was 227 million yuan, showing a year-on-year growth of 30.82% [3] - The sales gross margin stood at 84.74% [3] Market Position - As of April 1, the company's stock closed at 23.15 yuan, with a price-to-earnings (PE) ratio of 28.88 times, while the average PE ratio in the medical device industry is 46.46 times [1][3] - The company's total market capitalization is approximately 9.099 billion yuan [1] - In terms of market performance, the company ranked 65th in the industry based on PE ratio [1]

发明专利名称：一种探针及其适用于高通量测序的对目标区域进行富集的方 法 证券代码：300685 证券简称：艾德生物 公告编号：2025-013 厦门艾德生物医药科技股份有限公司 关于取得日本发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于近日收到日本特许厅颁发的发明专利证书。具体情况如下： 专利权人：厦门艾德生物医药科技股份有限公司 上述发明专利为公司自主研发，已在公司相关产品上应用。上述专利的取得 不会对公司近期生产经营产生重大影响，但有利于进一步完善公司知识产权保护 体系，充分发挥自主知识产权优势，促进技术创新，增强公司海外市场竞争力， 提升公司的综合实力。 厦门艾德生物医药科技股份有限公司 董 事 会 2025 年 3 月 10 日 专利号：特许第7641118号 专利类型：发明专利 专利申请日：2018年7月18日 专利权期限：自申请日起二十年 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-012 厦门艾德生物医药科技股份有限公司 关于回购股份注销完成暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"）本次 注销的回购股份数量为5,374,840股，占本次注销前公司总股本的1.35%，本次注销完成 后，公司总股本由398,436,809股变更为393,061,969股。 2、经中国证券登记结算有限责任公司深圳分公司确认，公司本次回购股份注销事 宜已于2025年3月4日办理完成。 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关 法律法规规定，现就本次回购公司股份注销完成的具体情况公告如下： 一、回购股份的实施情况 公司于 2024 年 2 月 26 日召开 2024 年第一次临时股东大会，审议通过了《关 于以集中竞价交易方式回购公司股份的议案》。根据本次回购方案，公司拟使用 自有资金以集中竞价方式回购股份用于注销并减少公司注册资本；回购资金总额 为不低于人民币 10,000 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-011 厦门艾德生物医药科技股份有限公司 关于回购股份期限届满暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于2024年2月26日召开2024年第一次临时股东大会，审议通过了《关于以集中竞 价交易方式回购公司股份的议案》。根据本次回购方案，公司拟使用自有资金以 集中竞价方式回购股份用于注销并减少公司注册资本；回购资金总额为不低于人 民币10,000万元且不超过人民币20,000万元，具体回购资金金额以回购实施完成 时实际回购的金额为准；回购股份的实施期限为自公司股东大会审议通过本次回 购方案之日起12个月内。具体内容详见公司于2024年2月26日刊登在巨潮资讯网 的《回购报告书》。 截至本公告披露日，公司本次回购股份方案的实施期限已届满，股份回购已 实施完成，现将本次回购的有关事项公告如下： 一、回购股份的实施情况 2024 年 3 月 29 日，公司首次通过回购专用证券账户以集中竞价交易方式实 施回购股份 1 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-010 产品名称：PD-L1抗体试剂（免疫组织化学法） 注册证编号：国械注准20223400313 变更内容：预期用途增加"本试剂盒用于体外定性检测经10%中性缓冲福尔 马 林 固 定 石 蜡 包 埋 （ FFPE ） 胃 / 胃 食 管 交 界 处 腺 癌 （ Gastric Adenocarcinoma/Gastroesophageal Adenocarcinoma，GA/GEA）组织切片中PD-L1 蛋白的表达情况，辅助鉴别可使用舒格利单抗联合化疗治疗的 GA/GEA患者，用 作舒格利单抗联合化疗的伴随诊断。"。 备注：本变更注册文件与"国械注准20223400313"注册证共同使用。 二、对公司的影响及风险提示 厦门艾德生物医药科技股份有限公司 关于公司收到医疗器械变更注册文件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"）于近日收到由国 家药品监督管理局颁发的《医疗器械变更注册文件》，公司已完成"PD-L1抗体 试剂（免疫组织化 ...